Downloads: 1
Original Research | Pharmacology and Toxicology | Volume 15 Issue 5, May 2026 | Pages: 781 - 783 | India
Assessment of Renal and Electrolyte Safety of Sacubitril / Valsartan in Patients with Heart Failure with Reduced Ejection Fraction in the Medicine Department of SMS Hospital, Jaipur
Abstract: Background: Heart failure with reduced ejection fraction is associated with high morbidity and mortality. Sacubitril/Valsartan is an important treatment option, but renal dysfunction and hyperkalemia remain important safety concerns requiring regular monitoring. Methods: This prospective observational study included 65 HFrEF patients receiving Sacubitril/Valsartan. Serum creatinine and serum potassium were assessed at baseline, 1 month, and 3 months and Statistical analysis was performed using SPSS, and associations were evaluated using the Chi-square test. Results: Among 65 patients, mean serum creatinine increased slightly from 0.87 to 0.89 mg/dL, and mean serum potassium increased from 4.19 to 4.69 mmol/L over 3 months. These changes were not statistically significant. Conclusion: Sacubitril/Valsartan showed acceptable short-term renal and electrolyte safety in HFrEF patients, with no significant change in serum creatinine or serum potassium over 3 months.
Keywords: Sacubitril, Valsartan, HFrEF, Renal safety, Electrolyte safety, Hyperkalemia
How to Cite?: Arun Kumar, Surendar Kumar, Jyotsana Bhargava, Kavita Bajiya, "Assessment of Renal and Electrolyte Safety of Sacubitril / Valsartan in Patients with Heart Failure with Reduced Ejection Fraction in the Medicine Department of SMS Hospital, Jaipur", Volume 15 Issue 5, May 2026, International Journal of Science and Research (IJSR), Pages: 781-783, https://www.ijsr.net/getabstract.php?paperid=SR26512122239, DOI: https://dx.dx.doi.org/10.21275/SR26512122239